benzodiazepine receptor were found for W-18 (K i =271 nM); W-15 displayed weak antagonist activity at 5-HT2-family serotonin receptors. W-18 is extensively metabolized, but its metabolites also lack opioid activity. W-18 and W-15 did inhibit hERG binding suggesting possible cardiovascular side-effects with high doses. Thus although W-18 and W-15 have been suggested to be potent opioid agonists, our results reveal no significant activity at these or other known targets for psychoactive drugs.
Here we describe the comprehensive pharmacological profiles of W-18 and W- 15 . Although W-18 and W-15 have been described as having potent antinociceptive activity and are presumed to interact with opioid receptors, we found them to be without detectible opioid activity at µ, δ, κ and nociception opioid receptors in a variety of assays. We also tested W-18 and W-15 for activity as allosteric modulators at opioid receptors and found them devoid of significant positive or negative allosteric modulatory activity. Comprehensive profiling at essentially all the druggable G-protein coupled receptors in the human genome using the PRESTO-Tango platform revealed no significant activity. In silico predictions using the Similarity Ensemble Approach suggested activity for W-18
only weakly at H3-histamine receptors, which was not confirmed in radioligand binding studies. Weak activity at the sigma receptors and the peripheral Psychoactive Drug Screening Program (NIMH-PDSP) as described 7 . Initial screens were performed at 10,000 nM in quadruplicate. For targets with inhibition > 50%, we also carried out concentration-response binding assays to determine affinities (K i ). Follow up assays on murine opioid receptors expressed in Chinese Hampster Ovary (CHO) cells were carried out as previously described 8 9 .
Metabolism studies. Metabolism was assessed using both mouse liver microsomes (MLM) and pooled human liver microsomes (HLM) incubated with NADPH (1 mM). Heat inactivated microsomes and incubations without NADPH were used as controls. At various time points 2-times volume of acetonitrile was added to stop the incubation and precipitate the protein so the sample could be analyzed by mass spectrometry. Samples were analyzed using multiple methods on a Sciex 6500 operating in multiple reaction monitoring mode using predicted mass transitions, using precursor ion and product ion scans. Samples were further analyzed on Thermo Scientific Q Exactive high resolution mass spectrometer using full scan mode operating at 70,000 resolution. Samples were also evaluated by HPLC using UV detection. HPLC-UV samples were processed by solid phase extraction, dried using a vacuum centrifuge and reconstituted in a minimal volume of mobile phase.
In addition, a W-18 mixed-metabolite sample was prepared by incubating 40 µl of a 20 mM W-18 DMSO stock with 5 ml of 1 mg/ml HLM or MLM and 1 mM NADPH for 90 minutes. Metabolites were isolated using solid phase extraction and dried using a speed vac. The mixed metabolite sample was re-solubilized and the pooled metabolites examined in opioid receptor binding assays using the murine receptors expressed in CHO cells at concentrations corresponding to an initial concentration of W-18 prior to the microsomes of 1 µM.
Opioid receptor functional assays. Assays for agonist and antagonist activity at cloned opioid receptors were performed as previously described using cloned, human κ 10 11 . µ 12 , δ, and nociceptin opioid receptors. 13 14 . Assays for evaluating the allosteric modulation of opioid receptors were performed using graded concentrations of potential allosteric modulators in the absence and presence of increasing concentrations of the orthosteric ligand in a manner similar to that recently described by us 15 .
Profiling of W-18 and W-15 against the druggable GPCR-ome. These studies were performed using our recently described PRESTO-Tango resource 16 , which allows for the unbiased interrogation of drugs against the entire, druggable GPCR-ome.
Predictive pharmacology. We used the Similarity Ensemble Approach 17-19 , essentially as previously described 17, 18, 20 to predict potential molecular targets for W-18 and W-15.
Data integrity and reproducibility. All dose-response assays were performed several times and replicated independently while the GPCR-ome analysis was performed twice in quadruplicate at different concentrations.
RESULTS
Radioligand binding assays reveal no activity of W-18 at human, cloned opioid receptors. In our initial studies we evaluated the ability of W-15 and W-18 to interact with three canonical opioid receptors via radioligand binding studies performed as previously described using cloned, human κ 10 11 . µ 12 , and δ opioid receptors (KOR, MOR and DOR, respectively). 13 14 . No significant inhibition of radioligand binding was measured up to concentrations as high as 10,000 nM (Table 1 ). These studies were followed by investigation of effects against the murine µ, κ and δ opioid receptors, with similar results. Figures 2 and 3 ). No significant agonist or antagonist activity was measured up to doses as high as 10,000 nM, although non-specific agonist effects were evident at high concentrations in these assays (Figs 2a-2d) We also evaluated the potential of W-18 to be allosteric modulators of opioid receptors and found no activities for either Gi or arrestin signaling (Figs 4-5) .
Functional assays reveal antagonist activity at human 5-HT receptors. Since W-15 and W-18 displayed binding activities at 5-HT 2 and 5-HT 6 receptors, we examined their functional activity at 5-HT 2A , 5-HT 2B , and 5-HT 2C receptors for calcium mobilization and at 5-HT 6 receptors for arrestin signaling. W-15 and W-18 showed no agonist activity and modest antagonist activity at 5-HT 2 receptors ( Fig 6) . Schild analysis with W-15 indicated competitive antagonism against 5-HT at 5-HT 2 receptors (Fig 7) . At 5-HT 6 receptors, W-15 and W-18 displayed no agonist activity (Fig 8) . W-15 and W-18 also displayed weak binding at A 1adenosine, α 2A -adrenergic, and CB 2 cannabinoid receptors, we therefore examined the nature of their activity at these receptors. Our results (Fig 8) indicated that they had no agonist activity at any of these examined receptors.
Screening of W-18 and W-15 against the druggable GPCR-ome reveals no
significant agonist activity at any human druggable GPCR. We next screened W-18 and W-15 against the druggable human GPCR-ome using our recently developed PRESTO-Tango resource 16 . Although no significant agonist activity was reproducibly found, we did note that concentrations of W-18 higher than 1 µM tended to cause a decrease in the overall baseline activity for nearly every target consistent with a toxic activity at HEK cells with prolongued incubation (not shown).
We In silico studies. We also used the Similarity Ensemble Approach to determine if any molecular targets might be predicted with high expectancies to have activity for W-18. No target(s) emerged with high confidence although weak predictions (E-value=4.67 e -1 ) suggested activity at were for H3-histamine for W-18 which was unconfirmed (Table 1 ).
In vivo evaluation. In the initial patent report W-18 was active in the writhing assay, with a potency many times that of morphine. When administered in mice at doses as high as Notes: BZP for brain benzodiazepine binding site (rat), PBR for peripheral benzodiazepine receptors.
SUPPLEMENTARY FIGURE 1: POTENTIAL SITES OF W-18 METABOLISM

